What records are connected here?
- Evidence lanes
- 3
- Source years
- 9
- Drugs@FDA applications
- 3
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Limited human dataHormones
Histrelin is a lab-made, more potent analogue of gonadotropin-releasing hormone (GnRH), a nine-amino-acid peptide, and the active ingredient in Supprelin LA.1,2 Supprelin LA is approved for children with central precocious puberty, in which puberty starts unusually early.1 Its approval rests on two small single-arm studies in children; in the larger, of 36 children, the main pubertal hormone was suppressed in every child through 12 months.1
| What it is | A synthetic nonapeptide analogue of gonadotropin-releasing hormone that, given continuously, suppresses the pituitary signals that drive puberty, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Supprelin LA, NDA 022058, with an original approval date of May 3, 2007. The cited label has no boxed warning.1,2 |
| Human evidence | Two single-arm, open-label studies in 11 and 36 children with central precocious puberty, described in the label.1 |
| Evidence strength | Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned |
Histrelin is a synthetic peptide of nine amino acids, an analogue of the natural gonadotropin-releasing hormone with greater potency, according to the label.1
In the United States it is the active ingredient of Supprelin LA, approved under NDA 022058, according to Drugs@FDA.2
The label states that histrelin first stimulates the release of the pituitary hormones LH and FSH, then, with continuous exposure, desensitizes the pituitary so that ovarian and testicular hormone production falls.1
Because of that initial stimulation, the label warns that estrogen or testosterone may rise briefly at the start and temporarily worsen signs of puberty.1
The label describes two single-arm, open-label studies. In the larger, of 36 children (33 girls and 3 boys), LH was suppressed in every child from month 1 through month 12.1
Estradiol was suppressed in all 33 girls through month 9 and in 97% at month 12, and testosterone stayed suppressed in the 3 boys, according to the label.1
Evidence-strength label: Limited human data. How this label is assigned
Yes. Drugs@FDA lists Supprelin LA, application NDA 022058, with an original approval date of May 3, 2007.2
The Supprelin LA label cited here (DailyMed SPL version 38, published September 29, 2025) states that it is indicated for the treatment of children with central precocious puberty.1
The label has no boxed warning. Its warnings include a temporary rise in sex hormones at the start, mood and behaviour changes such as irritability and aggression, and seizures reported with GnRH agonists.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Histrelin is not among them.3,4
How it compares with other treatments for central precocious puberty: the studies described in the label had no comparison group.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Histrelin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Histrelin are a bounded selection, not every registration or paper about Histrelin. For the years before Histrelin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Histrelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Histrelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Supprelin LA for central precocious puberty. Two small single-arm studies in children described in the label found that it suppressed pubertal hormones through 12 months. The studies had no comparison group.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Supprelin LA for central precocious puberty. Two small single-arm studies in children described in the label found that it suppressed pubertal hormones through 12 months. The studies had no comparison group.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date January 28, 2026
Histrelin for central precocious puberty-a single surgeon experience.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Histrelin for central precocious puberty-a single surgeon experience.↗Source date January 28, 2026Literature metadata · added November 16, 2026
Histrelin: in advanced prostate cancer.↗Source date October 20, 2021Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT00779103↗Source date January 8, 2021PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
1 of 1 selected trial records include at least one phase value; 1 of 1 include a status value in the retained structured contract.
5 of 5 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00779103 at 2026-11-16T01:35:22.086Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was histrelin.
The official Drugs@FDA dataset lists original submission 1 for NDA 019836 with status AP dated 1991-12-24, and names histrelin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 021732 with status AP dated 2004-10-12, and names histrelin acetate among the application record's active ingredients.
5 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span December 24, 1991 to January 28, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 25899147 in The Journal of surgical research as Journal Article, with publication-date metadata of 2015-03-30 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 20329807 in Drugs as Journal Article, Review, with publication-date metadata of 2010-03-26 (day precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00779103 at 2026-11-16T01:35:22.086Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was histrelin.↗
Literature metadata
PubMed lists PMID 2051345 in Journal of pharmaceutical sciences as Journal Article, with publication-date metadata of 1991-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 7684676 in Drugs as Journal Article, Review, with publication-date metadata of 1993-04 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 19228148 in BJU international as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-03 (month precision). PeptideScanner associated the retained record with the identity slug histrelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 022058 with status AP dated 2007-05-03, and names histrelin acetate among the application record's active ingredients.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 021732 with status AP dated 2004-10-12, and names histrelin acetate among the application record's active ingredients.↗
Regulatory
The Federal Register published notice 03-20949, attributed to FDA and its parent HHS department, on 2003-08-18. Its official title is “Eli Lilly and Co. et al.; Withdrawal of Approval of 80 New Drug Applications and 75 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Histrelin and Secretin.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 019836 with status AP dated 1991-12-24, and names histrelin acetate among the application record's active ingredients.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026